Mind the Byte opens an office in Toronto Blog Post

Mind the Byte, a pioneer company in the development of technologies based on artificial intelligence, cloud and big data for computational drug design, located in the Barcelona Science Park, announces the incorporation of a Canadian subsidiary, Mind the Byte Ltd, and the opening of a new office in Toronto. The new location in the heart of city’s tech hub is ideally situated in Canada’s largest biotech cluster, offering a range of opportunities for collaboration and partnership.

 

Creating the map of cells of the human body with support from the Chan Zuckerberg Initiative Blog Post

The Chan Zuckerberg Initiative (CZI) an advised fund of Silicon Valley Community Foundation, today announced new funding for 85 projects to support the Human Cell Atlas (HCA), a global effort to map every type of cell in the healthy human body as a resource for studies of health and disease. The grants total $15 million over one year. Holger Heyn, leader of the Single Cell Genomics team at the Centro Nacional de Análisis Genómico (CNAG-CRG), heads one of the projects selected for funding.

 

GalChimia opens an R&D centre in the Barcelona Science Park Blog Post

Galician company GalChimia –a specialist in organic chemistry products and services for the pharmaceutical industry– has today opened its R&D centre in the Barcelona Science Park to step up its growth and internationalisation strategy. With this first subsidiary the Galicia-based company expects to increase its turnover by 25% over the next two years and step up its growth and internationalisation plan.

 

RAC1 protein could be a new therapeutic target to fight neurodegeneration in Parkinson’s disease Blog Post

A new research study reveals RAC1 protein could be a new therapeutic target to study the molecular mechanisms related to the neurodegenerative processes in Parkinson’s disease. The study, published in the online edition of the journal Molecular Neurobiology, is led by Antonella Consiglio –head of the Laboratory of Stem Cells and Neuroplasticity at the Institute of Biomedicine of the UB (IBUB) in the Barcelona Science Park and researcher at the Faculty of Medicine and Health Sciences of the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL)– and Esther Dalfo, from the Univesitat Autònoma de Barcelona and Universitat de Vic – Universitat Central de Catalunya.

 

Oriol Segarra, CEO of Uriach, appointed member of the Board of Directors of Mind the Byte Blog Post

Mind the Byte, located at the Barcelona Science Park, announces the designation of Oriol Segarra, CEO of the pharmaceutical company Uriach, as a new member of the board of directors. With this appointment, the bioinformatics company –specializing in computational drug discovery using Big Data, Artificial Intelligence and Machine Learning technologies– wants to accelerate its business plan for its growth and internationalisation. 

 

QIAGEN enters into agreement to acquire STAT-Dx Blog Post

Qiagen, a Netherlands-based holding company has entered into an agreement to acquire Stat-Dx –a privately-held company with headquarters at the Barcelona Science Park– for $191 million. The catalan biotec, founded in 2010 by Jordi Carrera and Rafael Bru, is focused on the development, manufacturing and commercialization of “Closer to Care” diagnostic solutions.

 

EIT Health Wild Card: €4 million in search of innovative health ideas Blog Post

Under the new Wild Card programme, EIT Health consortium –the largest European body for innovation in healthy living and active ageing– has announced €4 million in funding for disruptive initiatives that help transform European healthcare and mitigate the social and economic impact of the progressive ageing of the population. The Universitat de Barcelona (UB), a core partner and promoter of EIT Health Spain, is one of the 14 European institutions that will offer advisory and incubation services to the two winning teams to turn their ideas into a business plan through of the Barcelona Entrepreneurship Institute (BIE), the Bosch i Gimpera Foundation (FBG) and the Barcelona Science Park (PCB). On Monday, January 29, an informative session will take place at the PCB.

 

Minoryx starts a phase II/III clinical study of MIN-102 for the treatment of adrenomyeloneuropathy Blog Post

Minoryx Therapeutics –a company specialized in the development of new drugs for orphan diseases, located at the Barcelona Science Park and the TecnoCampus Mataró– announces the start of its pivotal phase II/III clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy (AMN), the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD). The trial enrolls adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD).